Mastocytosis: current concepts in diagnosis and treatment
- PMID: 12483363
- DOI: 10.1007/s00277-002-0575-z
Mastocytosis: current concepts in diagnosis and treatment
Abstract
Mastocytosis consists of a group of disorders characterized by a pathologic increase in mast cells in tissues including skin, bone marrow, liver, spleen, and lymph nodes. Mastocytosis is a rare disease. Because of this, general practitioners have limited exposure to its clinical manifestations, diagnosis, classification, and management. Diagnosis of mastocytosis is suspected on clinical grounds and is established by histopathologic examination of involved tissues such as skin and bone marrow. The most common clinical sign of mastocytosis is the presence of typical skin lesions of urticaria pigmentosa. Most patients experience symptoms related to mast cell mediator release, and prevention of the effects of these mediators on tissues constitutes the major therapeutic goal in the management of mastocytosis. Despite recent advances in knowledge about the pathophysiology, diagnosis, and classification of mastocytosis, a curative treatment for mastocytosis does not now exist. Management of patients within all categories of mastocytosis includes: (1) a careful counseling of patients (parents in pediatric cases) and care providers, (2) avoidance of factors triggering acute mediator release, (3) treatment of acute mast cell mediator release, (4) treatment of chronic mast cell mediator release, and if indicated (5) an attempt to treat organ infiltration by mast cells. The goal of this manuscript is to provide an overview of the mediators produced and released by mast cells, the diagnostic criteria for the different variants of mastocytosis, and the treatment options currently available.
Similar articles
-
[Guidelines for the diagnosis, treatment and management of mastocytosis].An Sist Sanit Navar. 2008 Jan-Apr;31(1):11-32. An Sist Sanit Navar. 2008. PMID: 18496577 Review. Spanish.
-
[Mastocytosis, classification, biological diagnosis and therapy].Ann Biol Clin (Paris). 2004 Nov-Dec;62(6):657-69. Ann Biol Clin (Paris). 2004. PMID: 15563424 Review. French.
-
[Systemic mastocytosis. A review of current diagnostic and therapeutic approaches].Recenti Prog Med. 1999 Mar;90(3):169-72. Recenti Prog Med. 1999. PMID: 10228358 Review. Italian.
-
Biology, classification and treatment of human mastocytosis.Wien Klin Wochenschr. 1996;108(13):385-97. Wien Klin Wochenschr. 1996. PMID: 8766423 Review.
-
Mastocytosis: state of the art.Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. Pathobiology. 2007. PMID: 17587883 Review.
Cited by
-
Anesthetic considerations in pediatric mastocytosis: a review.J Anesth. 2013 Aug;27(4):588-98. doi: 10.1007/s00540-013-1563-2. Epub 2013 Feb 14. J Anesth. 2013. PMID: 23408045 Review.
-
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.Cancers (Basel). 2022 Jan 31;14(3):738. doi: 10.3390/cancers14030738. Cancers (Basel). 2022. PMID: 35159005 Free PMC article.
-
Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.F1000Res. 2016 Nov 14;5:2666. doi: 10.12688/f1000research.9565.1. eCollection 2016. F1000Res. 2016. PMID: 27909577 Free PMC article. Review.
-
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.Exp Hematol. 2010 Oct;38(10):896-907. doi: 10.1016/j.exphem.2010.05.008. Epub 2010 Jun 1. Exp Hematol. 2010. PMID: 20570632 Free PMC article.
-
IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.Vet Comp Oncol. 2017 Dec;15(4):1240-1256. doi: 10.1111/vco.12260. Epub 2016 Aug 9. Vet Comp Oncol. 2017. PMID: 27507155 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources